Recent Announcements
PhotoPharmics to Present Patient Interest Findings from Groundbreaking Remote Parkinsonās Trial at PSG Annual Meeting
Presentation to Highlight Feasibility and Interest in Decentralized Home-Based Phase 3 Trial Salt...
PhotoPharmics Announces First Subject Completes FDA Pivotal Clinical Trial for the Celeste Device in Parkinsonās
PhotoPharmics, a leader in non-invasive phototherapy for neurological disorders, has reached a significant milestone in its ongoing FDA pivotal āLight for PDā trial for the Celeste therapeutic device. The first subject has successfully completed the full 6-month treatment course and clinical visits, marking an important step towards the successful completion of the trial and future FDA authorization of Celeste in treating Parkinsonās disease (PD).
PhotoPharmics Welcomes Three Renowned Experts to Its Clinical & Scientific Advisory Board
PhotoPharmics, an innovator in light-based therapies for neurodegenerative diseases, proudly announces the appointment of three eminent experts to its Clinical & Scientific Advisory Board (CSAB). The new membersāDr. Charles H. Adler, Dr. George Brainard, and Dr. Robert A. Hauserābring unparalleled expertise to the advisory board, reinforcing PhotoPharmics’ mission to pioneer groundbreaking treatments for Parkinsonās disease and other neurodegenerative disorders.
Featured Article
An Overview of Parkinsonās Disease
What is Parkinsonās? Parkinsonās Disease (PD) is a complex neurodegenerative disorder that affects the nervous system and progressively worsens over time.Ā While motor symptomsāsuch as tremors, stiffness, and slow movementāare often the most observable and commonly...
An Overview of Parkinsonās Disease
What is Parkinsonās? Parkinsonās Disease (PD) is a complex neurodegenerative disorder that affects the nervous system and progressively worsens over time.Ā While motor symptomsāsuch as tremors, stiffness, and slow movementāare often the most observable and commonly...
Archived Content